Application No.: 10/617,266 3 , Docket No.: 01946/100B035-USC

AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

Claims 1-29 (Canceled).

30. (Currently Amended) The compound

and salts thereof.

- 31. (Canceled)
- 32. (Previously Presented) A composition comprising
 - a. an active agent; and
 - b. the compound of claim 30.
- 33. (Previously Presented) A composition as defined in claim 32, wherein said active agent is selected from the group consisting of a pharmacologic agent and a therapeutic active agent.
- 34. (Previously Presented) A composition as defined in claim 32, wherein said active agent is selected from the group consisting of a biologically active agent and a chemically active agent.

Application No.: 10/617,266 4 Docket No.: 01946/100B035-USC

35. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.

- 36. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a peptide.
- 37. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a polysaccharide.
- 38. (Previously Presented) A composition as defined in claim 35, wherein said active agent comprises a mixture of mucopolysaccharides.
- 39. (Previously Presented) A composition as defined in claim 34, wherein said biologically active agent is a hormone.
- 40. (Currently Amended) A composition as defined in claim 34 38, wherein said mixture of mucopolysaccharides comprises heparin.
- 41. (Currently Amended) A composition as defined in claim 34, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth releasing hormones; growth hormone-releasing hormones, interferons; interleukin-I, interleukin-II, insulin; heparin, calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies, somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbials, or any combination thereof.
- 42. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises insulin.

43. (Currently Amended) A composition as defined in claim 42 41, wherein said heparin comprises low molecular weight heparin.

- 44. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises calcitonin.
- 45. (Previously Presented) A composition as defined in claim 41, wherein said biologically active agent comprises human growth hormone.
- 46. (Previously Presented) The composition of claim 41, wherein said biologically active agent comprises parathyroid hormone.
- 47. (Previously Presented) A dosage unit form comprising a composition as defined in claim 32; and
 - a. an excipient,
 - b. a diluent,
 - c. a disintegrant,
 - d. a lubricant,
 - e. a plasticizer,
 - f. a colorant,
 - g. a dosing vehicle, or
 - h. any combination thereof.
- 48. (Previously Presented) A dosage unit form according to claim 47, comprising a tablet, a capsule, or a liquid.

Application No.: 10/617,266 6 Docket No.: 01946/100B035-USC

49. (Previously Presented) A dosage unit form according to claim 48, consisting of a tablet.

- 50. (Previously Presented) A dosage unit form according to claim 48, consisting of a capsule.
- 51. (Previously Presented) The dosage unit form of claim 47, wherein said active agent is selected from the group consisting of a biologically active agent and a chemically active agent.
- 52. (Previously Presented) The dosage unit form of claim 51, wherein said biologically active agent is selected from the group consisting of a peptide, a polysaccharide, a mucopolysaccharide, a carbohydrate, a lipid, a pesticide, and any combination thereof.
- 53. (Previously Presented) The dosage unit form of claim 52, wherein said active agent comprises a polysaccharide.
- 54. (Previously Presented) The dosage unit form of claim 52, wherein said active agent comprises a peptide.
- 55. (Previously Presented) The dosage unit form of claim 52, wherein said active agent comprises a mixture of mucopolysaccharides.
- 56. (Previously Presented) The dosage unit form of claim 55, wherein said mixture of mucopolysaccharides comprises heparin.
- 57. (Currently Amended) The dosage unit form of claim 51, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth releasing hormones; growth hormone-releasing hormones; interferons; interleukin-I, interleukin-II; insulin; heparin, calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing

Application No.: 10/617,266 7 Docket No.: 01946/100B035-USC

hormone; oxytocin; vasopressin; cromolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbials, or any combination thereof.

- 58. (Previously Presented) The dosage unit form of claim 57, wherein said heparin comprises low molecular weight heparin.
- 59. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises insulin.
- 60. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises parathyroid hormones.
- 61. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises calcitonin.
- 62. (Previously Presented) The dosage unit form of claim 57, wherein said biologically active agent comprises human growth hormone.
- 63. (Previously Presented) A method for preparing a composition, said method comprising mixing:
 - a. at least one biologically active agent;
 - b. at least one compound as defined in claim 30; and
 - c. optionally a dosing vehicle.
- 64. (Previously Presented) A method as defined in claim 63, wherein said biologically active agent comprises a peptide.
- 65. (Previously Presented) A method as defined in claim 63, wherein said biologically active agent comprises polysaccharide.

Application No.: 10/617,266 8 Docket No.: 01946/100B035-USC

66. (Currently Amended) A method as defined in claim 63 65, wherein said polysaccharide comprises a mixture of muco-polysaccharides.

- 67. (Currently Amended) The method of claim 63, wherein said biologically active agent is selected from the group consisting of human growth hormones; bovine growth hormones; growth releasing hormones; growth hormone-releasing hormones; interferons; interleukin-I; interleukin-II; insulin; heparin, calcitonin; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; vasopressin; cromolyn sodium; vancomycin; desferrioxamine (DFO); parathyroid hormone, anti-microbial, or any combination thereof.
- 68. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering to said animal a composition as defined in claim 32.
- 69. (Currently Amended) A method for administering an biologically- active agent as defined in claim 68, wherein said administration is oral.
- 70. (Currently Amended) A method for administering an biologically- active agent as defined in claim 68, wherein said animal is a mammal.
- 71. (Currently Amended) A method for administering an biologically- active agent as defined in claim 70, wherein said mammal is a human.
- 72. (Currently Amended) A method for administering an biologically- active agent as defined in claim 68, wherein said composition is a solid.
- 73. (Currently Amended) A method for administering an biologically- active agent as defined in claim 72, wherein said composition is a tablet or capsule.

Application No.: 10/617,266 9 Docket No.: 01946/100B035-USC

74. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 36.

- 75. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 38.
- 76. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 40.
- 77. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 42.
- 78. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 43.
- 79. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 44.
- 80. (Currently Amended) A method for administering an biologically- active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 45.
- 81. (Currently Amended) A method for administering an biologically—active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 46.